Welcome to the Predictive Oncology Thought Leadership Series.
Discover how pioneering innovations in artificial intelligence (AI) and machine learning (ML) are accelerating early-stage drug discovery and de-risking late-stage drug development. Over the next three weeks, we will provide valuable insights into the power of Controlled Biobanking, the significance of Patient Heterogeneity and the impact on target validation, biomarker discovery, probability of technical success, Clinical Trial Design and Clinical Decision Support.
Please join us to learn more about the latest breakthroughs in AI-driven drug discovery in oncology.
Biobank content goes here.